BioStock: New data gives weight to Ultimovacs’s cancer vaccine

It would seem like Ultimovacs is on to something with its cancer vaccine UV1. New data from their phase I trial with UV1 and checkpoint inhibitor pembrolizumab in advanced malignant melanoma patients suggests that the combination increases survival times and reduces tumour size or makes tumours disappear. The full results, which will be presented at the ASCO conference in June, are a testament to the combination potential that UV1 has not only in melanoma, but in other cancers as well.

Read the full article at biostock.se:

https://www.biostock.se/en/new-data-gives-weight-to-ultimovacss-cancer-vaccine/

This is a press release from BioStock - Connecting Innovation & Capital.